Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

scientific article published on 05 January 2012

Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/10428194.2011.623258
P698PubMed publication ID21919823

P50authorLuca BaldiniQ39052059
Agostino CortelezziQ56461136
Antonino NeriQ56850455
Giuseppe GrittiQ57078362
Gianluigi RedaQ59647804
Stefano MolicaQ59660152
Francesco MauraQ92130305
P2093author name stringAlfonso Piciocchi
P433issue3
P921main subjectchronic lymphocytic leukemiaQ1088156
P304page(s)424-429
P577publication date2012-01-05
P1433published inLeukemia & LymphomaQ6534493
P1476titleLow dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
P478volume53

Reverse relations

cites work (P2860)
Q36892621A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Q36768605Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use
Q27022373New antibody approaches to lymphoma therapy
Q37147789New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia
Q36300303Therapeutic advancement of chronic lymphocytic leukemia